Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report sent to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group lowered shares of Brainstorm Cell Therapeutics from a buy rating to a hold rating in a report on […]